Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women

被引:48
作者
Johansson, E
Brache, V
Alvarez, F
Faundes, A
Cochon, L
Ranta, S
Lovern, M
Kumar, N
机构
[1] PROFAMILIA, Biomed Res Dept, Santo Domingo, Dominican Rep
[2] Populat Council, Ctr Biomed Res, New York, NY 10021 USA
[3] CEMICAMP, Campinas, SP, Brazil
[4] Univ Helsinki, Inst Biomed, Steroid Res Lab, Helsinki, Finland
[5] Pharsight Corp, Cary, NC USA
关键词
emergency contraception; levonorgestrel; pharmacokinetics; SHBG;
D O I
10.1093/humrep/17.6.1472
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use. METHODS: Serum levels of LNG and sex hormone-binding globulin (SHBG) were measured in five women who received three different regimens: A: 0.75 mg LNG twice with a 12 h interval; B: 0.75 mg twice with a 24 h interval; and C: 1.50 mg in a single dose, with a washout period of 28 days between each treatment. Blood samples were taken before pill intake and at 1, 2, 4, 8 and 12 h after each dose, every 12 h up to day 4 and every 24 h until day 10. LNG and SHBG were measured in all samples. RESULTS: Maximum LNG concentrations were of similar to27 nmol/l for treatments A and B, and close to 40 nmol/l for treatment C. The area under the curve was significantly higher for treatment C during the first 12 h, and significantly lower for treatment B during the first 24 h. After 48 h and up to 9 days from onset of treatment, serum LNG levels were similar in all three regimens. SHBG levels remained stable for 24 h, decreasing to 60% of the initial value from day 5 until day 10, with no difference between regimens. CONCLUSIONS: The similarity of LNG serum levels obtained with one single dose of 1.5 mg or two doses of 0.75 mg with a 12 h interval justify a clinical comparison of these two regimes.
引用
收藏
页码:1472 / 1476
页数:5
相关论文
共 15 条
  • [1] BERER M, 1995, CONTRACEPTION, V52, P211
  • [2] Timing of onset of contraceptive effectiveness in Norplant® implant users II -: Effect on the ovarian function in the first cycle of use
    Brache, V
    Blumenthal, PD
    Alvarez, F
    Dunson, TR
    Cochon, L
    Faundes, A
    [J]. CONTRACEPTION, 1999, 59 (04) : 245 - 251
  • [3] Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function
    Croxatto, HB
    Fuentealba, B
    Brache, V
    Salvatierra, AM
    Alvarez, F
    Massai, R
    Cochon, L
    Faundes, A
    [J]. CONTRACEPTION, 2002, 65 (02) : 121 - 128
  • [4] Grimes D, 1998, LANCET, V352, P428
  • [5] COMPARATIVE CROSS-OVER PHARMACOKINETIC STUDY ON 2 TYPES OF POSTCOITAL CONTRACEPTIVE TABLETS CONTAINING LEVONORGESTREL
    HE, CH
    SHI, YE
    LIAO, DL
    ZHU, YH
    XU, JQ
    MATLIN, SA
    VINCE, PM
    FOTHERBY, K
    VANLOOK, PFA
    [J]. CONTRACEPTION, 1990, 41 (05) : 557 - 567
  • [6] A PROSPECTIVE RANDOMIZED COMPARISON OF LEVONORGESTREL WITH THE YUZPE REGIMEN IN POST-COITAL CONTRACEPTION
    HO, PC
    KWAN, MSW
    [J]. HUMAN REPRODUCTION, 1993, 8 (03) : 389 - 392
  • [7] HORMONAL AND PERIPHERAL EFFECTS OF D-NORGESTREL IN POSTCOITAL CONTRACEPTION
    KESSERU, E
    GARMENDIA, F
    WESTPHAL, N
    PARADA, J
    [J]. CONTRACEPTION, 1974, 10 (04) : 411 - 424
  • [8] THE EFFECT OF LEVONORGESTREL ADMINISTERED IN LARGE DOSES AT DIFFERENT STAGES OF THE CYCLE ON OVARIAN-FUNCTION AND ENDOMETRIAL MORPHOLOGY
    LANDGREN, BM
    JOHANNISSON, E
    AEDO, AR
    KUMAR, A
    SHI, YE
    [J]. CONTRACEPTION, 1989, 39 (03) : 275 - 289
  • [9] LARRANAGA A, 1971, EXCERPTA MED INT C S, V234, P87
  • [10] Seregely G, 1982, Ther Hung, V30, P72